Exacis Biotherapeutics CEO to Serve on Panel at Longwood Healthcare Leaders Fall Webconference

Dr. Gregory Fiore, Co-Founder, President and CEO of Exacis Biotherapeutics will join an expert panel of biotechnology leaders to discuss “Placing Patients at the Center” during the Longwood Healthcare Leaders Fall webconference. As a physician and CEO of Exacis, Dr. Fiore’s passion is to ensure that the field of cell therapy maintains its focus on improving the outcomes and experiences of oncology patients while increasing affordability and access to care.

“I am honored to join this panel of thoughtful experts bringing a variety of perspectives related to patient-centricity,” said Dr. Fiore. “Helping patients is what drives each of us and I am excited to learn from the co-panelists experiences about ideas we can build into our activities at Exacis.”

The panel will take place at 3:20 pm ET on Thursday, September 22.

The Longwood Healthcare Leaders Fall webconference will be held September 21-22, 2022. Hosted by the Longwood Fund, an early-stage life science venture firm, the conference will bring together leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors for an off-the-record forum focused on accelerating the translation of discoveries into medicines to help patients.

Exacis is a development stage immuno-oncology company focused on harnessing the human immune system to cure cancer by engineering next generation off-the-shelf NK and T cell therapies aimed at hematologic malignancies and solid tumors. Exacis was founded in 2020 with an exclusive global license to a broad suite of patents covering the use of mRNA based cell reprogramming and gene editing technologies for use in generating engineered NK and T cells for oncology applications.

Exacis’ approach avoids the use of DNA and viruses and instead uses a proprietary mRNA based technology. Exacis uses the technology to generate iPSCs and to edit their genome to create stealthed, performance enhanced allogeneic NK and T cell products, termed ExaNK™, ExaCAR-NK™ and ExaCAR-T™ cells.

T and NK cells are types of human immune cells that are able to recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.

Contact Exacis Biotherapeutics for further information and media: 

Exacis Biotherapeutics 

info@exacis.com